Akebia signals 7x increase in patient access for Vafseo entering 2026 amid operational focus
Source: SeekingAlpha
2025-11-10 11:02:38 ET
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
- Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core
- Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
- Akebia GAAP EPS of $0.00 beats by $0.01, revenue of $58.78M beats by $2.36M
- Akebia Q3 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Akebia signals 7x increase in patient access for Vafseo entering 2026 amid operational focus
Akebia Therapeutics Inc.
NASDAQ: AKBA
AKBA Trading
1.45% G/L:
$1.395 Last:
1,187,178 Volume:
$1.40 Open:
AKBA Latest News
March 03, 2026 08:00:00 am
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026 07:00:00 am
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
AKBA Stock Data
$399,375,819
257,405,013
0.93%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
